China SXT Pharmaceuticals, Inc. (SXTC)

NASDAQ: SXTC · IEX Real-Time Price · USD
0.750
+0.065 (9.52%)
At close: Dec 2, 2022 4:00 PM
0.852
+0.102 (13.65%)
Pre-market: Dec 5, 2022 5:40 AM EST
9.52%
Market Cap 1.84M
Revenue (ttm) 339,126
Net Income (ttm) -5.74M
Shares Out 1.04M
EPS (ttm) -9.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 334,557
Open 0.71
Previous Close 0.685
Day's Range 0.69 - 0.77
52-Week Range 0.09 - 2.28
Beta 0.57
Analysts n/a
Price Target n/a
Earnings Date n/a

About SXTC

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang bra... [Read more]

Industry Personal Products
IPO Date Jan 4, 2019
Employees 88
Stock Exchange NASDAQ
Ticker Symbol SXTC
Full Company Profile

Financial Performance

In 2021, SXTC's revenue was $339,126, a decrease of -61.68% compared to the previous year's $884,990. Losses were -$5.74 million, 108.7% more than in 2020.

Financial Statements

News

China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development,...

6 months ago - GlobeNewsWire

Why Is China SXT Pharmaceuticals (SXTC) Stock Up Today?

SXTC stock is soaring higher on no company-specific news. Positive developments between the U.S. and China may be fueling gains.

8 months ago - InvestorPlace

China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note i...

TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) --  China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, m...

8 months ago - GlobeNewsWire

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclu...

NEW YORK, NY / ACCESSWIRE / January 20, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China ...

10 months ago - Accesswire

China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordin...

TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, man...

10 months ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Wa...

TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, man...

10 months ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded War...

TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, man...

10 months ago - GlobeNewsWire

China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces th...

TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, man...

10 months ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

TAIZHOU, China, Dec. 16, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC) announced today that on December 14, 2021, the Company received a notification let...

11 months ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Insp...

TAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, man...

1 year ago - PRNewsWire

China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split

TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, man...

1 year ago - PRNewsWire